UNSPSC 51271631: Lidocaine hydrochloride monohydrate

This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C14H22N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V13007Z41A, chemically known as acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, but more generally known as lidocaine hydrochloride monohydrate, which bears US NIH Compound Identifier 22483.

European Medicines Agency schedules lidocaine hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG. Most nations, for tariff purposes, schedule lidocaine hydrochloride monohydrate under HS 29242910. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.O.CL.

UNSPSC 51271631 Lidocaine hydrochloride monohydrate is a Commodity code encompassing branded and generic pharmaceuticals sold through state and local procurement channels, particularly for distribution to healthcare facilities, correctional institutions, and emergency services. State and local governments procure lidocaine hydrochloride monohydrate and similar injectable anesthetics and topical analgesics as part of broader pharmaceutical supply agreements that bundle generic multi-source drugs and over-the-counter products. Issuing bodies include state procurement offices and cooperative purchasing alliances that aggregate demand across multiple member jurisdictions — both state agencies and local government entities — to negotiate volume pricing and standardized supply agreements with manufacturers and authorized pharmaceutical wholesalers. The procurement approach favors manufacturers capable of maintaining relationships with major drug distribution networks, providing comprehensive product data including National Drug Codes and packaging specifications, and certifying compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026. Awarded vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain commercial general liability coverage of $5,000,000 per occurrence, comply with FDA requirements, and agree to a 3 percent administrative fee on all contract purchases. The contract term is two years for new responders with optional extensions, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. Evaluation is weighted heavily toward price competitiveness (75 percent), with remaining points allocated to fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to the 3 percent administrative fee (5 percent).